Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test reveals why lung cancer drugs stop working

NCT ID NCT04087473

NEW Completed Knowledge-focused Sponsor: National Cancer Centre, Singapore Source: ClinicalTrials.gov ↗

First seen May 16, 2026 · Last updated May 16, 2026

Summary

This study looked at blood samples from 50 people with a specific type of lung cancer (ALK-positive) whose cancer had stopped responding to treatment. The goal was to find genetic changes in the blood that explain drug resistance, so doctors can choose the next treatment more effectively. Participants had already tried 1-2 ALK inhibitor drugs. The research aimed to improve outcomes by matching the right drug to the right resistance mutation.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Asan Medical Centre

    Seoul, 05505, South Korea

  • National Cancer Center Singapore

    Singapore, 169690, Singapore

  • Seoul National University Hospital

    Seoul, South Korea

  • The Chinese University of Hong Kong

    Hong Kong, Hong Kong

  • University Malaya Medical Centre

    Kuala Lumpur, Malaysia

Conditions

Explore the condition pages connected to this study.

ALK-POSITIVE LUNG CANCER NON-SMALL CELL LUNG CANCER